Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Magnesium sulfate | The therapeutic efficacy of Harmaline can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Harmaline may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Orphenadrine | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Harmaline. |
| Pramipexole | Harmaline may increase the sedative activities of Pramipexole. |
| Ropinirole | Harmaline may increase the sedative activities of Ropinirole. |
| Rotigotine | Harmaline may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Harmaline. |
| Sodium oxybate | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Thalidomide | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Harmaline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Desmopressin | The risk or severity of hypertension can be increased when Desmopressin is combined with Harmaline. |
| Cyclosporine | The risk or severity of hypertension can be increased when Cyclosporine is combined with Harmaline. |
| Icosapent | The risk or severity of hypertension can be increased when Icosapent is combined with Harmaline. |
| Mesalazine | The risk or severity of hypertension can be increased when Mesalazine is combined with Harmaline. |
| Indomethacin | The risk or severity of hypertension can be increased when Indomethacin is combined with Harmaline. |
| Methylergometrine | The risk or severity of hypertension can be increased when Methylergometrine is combined with Harmaline. |
| Nabumetone | The risk or severity of hypertension can be increased when Nabumetone is combined with Harmaline. |
| Ketorolac | The risk or severity of hypertension can be increased when Ketorolac is combined with Harmaline. |
| Tenoxicam | The risk or severity of hypertension can be increased when Tenoxicam is combined with Harmaline. |
| Celecoxib | The risk or severity of hypertension can be increased when Celecoxib is combined with Harmaline. |
| Tolmetin | The risk or severity of hypertension can be increased when Tolmetin is combined with Harmaline. |
| Rofecoxib | The risk or severity of hypertension can be increased when Rofecoxib is combined with Harmaline. |
| Piroxicam | The risk or severity of hypertension can be increased when Piroxicam is combined with Harmaline. |
| Fenoprofen | The risk or severity of hypertension can be increased when Fenoprofen is combined with Harmaline. |
| Valdecoxib | The risk or severity of hypertension can be increased when Valdecoxib is combined with Harmaline. |
| Diclofenac | The risk or severity of hypertension can be increased when Diclofenac is combined with Harmaline. |
| Sulindac | The risk or severity of hypertension can be increased when Sulindac is combined with Harmaline. |
| Nicergoline | The risk or severity of hypertension can be increased when Nicergoline is combined with Harmaline. |
| Flurbiprofen | The risk or severity of hypertension can be increased when Flurbiprofen is combined with Harmaline. |
| Etodolac | The risk or severity of hypertension can be increased when Etodolac is combined with Harmaline. |
| Mefenamic acid | The risk or severity of hypertension can be increased when Mefenamic acid is combined with Harmaline. |
| Naproxen | The risk or severity of hypertension can be increased when Naproxen is combined with Harmaline. |
| Sulfasalazine | The risk or severity of hypertension can be increased when Sulfasalazine is combined with Harmaline. |
| Phenylbutazone | The risk or severity of hypertension can be increased when Phenylbutazone is combined with Harmaline. |
| Meloxicam | The risk or severity of hypertension can be increased when Meloxicam is combined with Harmaline. |
| Carprofen | The risk or severity of hypertension can be increased when Carprofen is combined with Harmaline. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Harmaline. |
| Diflunisal | The risk or severity of hypertension can be increased when Diflunisal is combined with Harmaline. |
| Salicylic acid | The risk or severity of hypertension can be increased when Salicylic acid is combined with Harmaline. |
| Meclofenamic acid | The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Harmaline. |
| Dopamine | The risk or severity of hypertension can be increased when Dopamine is combined with Harmaline. |
| Oxaprozin | The risk or severity of hypertension can be increased when Oxaprozin is combined with Harmaline. |
| Ketoprofen | The risk or severity of hypertension can be increased when Ketoprofen is combined with Harmaline. |
| Balsalazide | The risk or severity of hypertension can be increased when Balsalazide is combined with Harmaline. |
| Ibuprofen | The risk or severity of hypertension can be increased when Ibuprofen is combined with Harmaline. |
| Dutasteride | The risk or severity of hypertension can be increased when Dutasteride is combined with Harmaline. |
| Propafenone | The risk or severity of hypertension can be increased when Propafenone is combined with Harmaline. |
| Finasteride | The risk or severity of hypertension can be increased when Finasteride is combined with Harmaline. |
| Lumiracoxib | The risk or severity of hypertension can be increased when Lumiracoxib is combined with Harmaline. |
| Ephedrine | The risk or severity of hypertension can be increased when Ephedrine is combined with Harmaline. |
| Magnesium salicylate | The risk or severity of hypertension can be increased when Magnesium salicylate is combined with Harmaline. |
| Salsalate | The risk or severity of hypertension can be increased when Salsalate is combined with Harmaline. |
| Choline magnesium trisalicylate | The risk or severity of hypertension can be increased when Choline magnesium trisalicylate is combined with Harmaline. |
| Antrafenine | The risk or severity of hypertension can be increased when Antrafenine is combined with Harmaline. |
| Aminophenazone | The risk or severity of hypertension can be increased when Aminophenazone is combined with Harmaline. |
| Antipyrine | The risk or severity of hypertension can be increased when Antipyrine is combined with Harmaline. |
| Tiaprofenic acid | The risk or severity of hypertension can be increased when Tiaprofenic acid is combined with Harmaline. |
| Etoricoxib | The risk or severity of hypertension can be increased when Etoricoxib is combined with Harmaline. |
| Epicaptopril | The risk or severity of hypertension can be increased when Epicaptopril is combined with Harmaline. |
| Taxifolin | The risk or severity of hypertension can be increased when Taxifolin is combined with Harmaline. |
| Oxyphenbutazone | The risk or severity of hypertension can be increased when Oxyphenbutazone is combined with Harmaline. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Harmaline. |
| Benoxaprofen | The risk or severity of hypertension can be increased when Benoxaprofen is combined with Harmaline. |
| Metamizole | The risk or severity of hypertension can be increased when Metamizole is combined with Harmaline. |
| Zomepirac | The risk or severity of hypertension can be increased when Zomepirac is combined with Harmaline. |
| Dronedarone | The risk or severity of hypertension can be increased when Dronedarone is combined with Harmaline. |
| Cimicoxib | The risk or severity of hypertension can be increased when Cimicoxib is combined with Harmaline. |
| Amibegron | The risk or severity of hypertension can be increased when Amibegron is combined with Harmaline. |
| Nylidrin | The risk or severity of hypertension can be increased when Nylidrin is combined with Harmaline. |
| Solabegron | The risk or severity of hypertension can be increased when Solabegron is combined with Harmaline. |
| Lornoxicam | The risk or severity of hypertension can be increased when Lornoxicam is combined with Harmaline. |
| Aceclofenac | The risk or severity of hypertension can be increased when Aceclofenac is combined with Harmaline. |
| Zaltoprofen | The risk or severity of hypertension can be increased when Zaltoprofen is combined with Harmaline. |
| Saralasin | The risk or severity of hypertension can be increased when Saralasin is combined with Harmaline. |
| Azapropazone | The risk or severity of hypertension can be increased when Azapropazone is combined with Harmaline. |
| Parecoxib | The risk or severity of hypertension can be increased when Parecoxib is combined with Harmaline. |
| Salicylamide | The risk or severity of hypertension can be increased when Salicylamide is combined with Harmaline. |
| Tyramine | The risk or severity of hypertension can be increased when Tyramine is combined with Harmaline. |
| Mirabegron | The risk or severity of hypertension can be increased when Mirabegron is combined with Harmaline. |
| Adrafinil | The risk or severity of hypertension can be increased when Adrafinil is combined with Harmaline. |
| Kebuzone | The risk or severity of hypertension can be increased when Kebuzone is combined with Harmaline. |
| Isoxicam | The risk or severity of hypertension can be increased when Isoxicam is combined with Harmaline. |
| Indoprofen | The risk or severity of hypertension can be increased when Indoprofen is combined with Harmaline. |
| Ibuproxam | The risk or severity of hypertension can be increased when Ibuproxam is combined with Harmaline. |
| Floctafenine | The risk or severity of hypertension can be increased when Floctafenine is combined with Harmaline. |
| Fenbufen | The risk or severity of hypertension can be increased when Fenbufen is combined with Harmaline. |
| Etofenamate | The risk or severity of hypertension can be increased when Etofenamate is combined with Harmaline. |
| Etilefrine | The risk or severity of hypertension can be increased when Etilefrine is combined with Harmaline. |
| Epirizole | The risk or severity of hypertension can be increased when Epirizole is combined with Harmaline. |
| Benzydamine | The risk or severity of hypertension can be increased when Benzydamine is combined with Harmaline. |